# Fennec Pharmaceuticals

Source: https://onco.cc/companies/fennec-pharmaceuticals/  
OnCo record `fennec-pharmaceuticals` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Fennec Pharmaceuticals is the North Carolina company behind Pedmark, the sodium thiosulfate infusion given after cisplatin to protect children's hearing from the chemotherapy.

## Summary

Fennec Pharmaceuticals, formerly Adherex Technologies, developed Pedmark (sodium thiosulfate) as an otoprotectant. Given six hours after each cisplatin dose, it neutralises the platinum that damages inner-ear hair cells; the SIOPEL 6 and ACCL0431 trials showed roughly halved rates of hearing loss in children with localised solid tumours. The FDA approved Pedmark in September 2022 for patients aged one month and older, and the European Union approved it as Pedmarqsi in 2023.

## Fields

- Kind: Company
- Last checked: 2026-09-17
- Also known as: Adherex Technologies; Fennec Pharmaceuticals Inc.; NASDAQ:FENC
- Tags: drug-maker
- HQ: Research Triangle Park, North Carolina
- Type: pharma
- Website: https://www.fennecpharma.com/
- Ticker: NASDAQ:FENC

## Sources

- Official website: https://www.fennecpharma.com/

## Connected records

- drugs: [Sodium thiosulfate (otoprotectant)](https://onco.cc/drugs/sodium-thiosulfate/)

---
JSON: https://onco.cc/api/v1/entities/fennec-pharmaceuticals.json